MGNXMacroGenics, Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 18526
Ticker: MGNX
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2013-10-10
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: MGNX

Detail

Enriched 2026-08-14 20:47

Market cap: $255,523,754.46
Shares outstanding (class): 63,563,123
Shares outstanding (weighted): 63,563,123
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 293
Location: Rockville, MD
Homepage: https://www.macrogenics.com
Description: Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Market cap and share counts drift.

Funds holding this security

26 funds · 26 positions · $17.36M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$5.56M	0.00%	1,925,510 NS	FIGI
Wasatch Ultra Growth Fund WASATCH FUNDS TRUST	—	$4.14M	1.03%	1,433,988 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$1.88M	0.00%	651,752 NS	FIGI
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS	—	$1.27M	0.05%	438,601 NS	FIGI
SMALL COMPANY GROWTH PORTFOLIO VANGUARD VARIABLE INSURANCE FUNDS	—	$1.26M	0.09%	437,607 NS	FIGI
Nomura Healthcare Fund Delaware Group Equity Funds IV	—	$1.21M	0.18%	420,000 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$428.0K	0.04%	148,109 NS	FIGI
Wasatch Long/Short Alpha Fund WASATCH FUNDS TRUST	—	$277.5K	0.78%	96,036 NS	FIGI
Ultra-Small Company Market Fund Bridgeway Funds, Inc.	—	$212.4K	0.17%	73,500 NS	FIGI
SMALL CAP EQUITY FUND GuideStone Funds	—	$177.3K	0.02%	61,341 NS	FIGI
NVIT Multi-Manager Small Company Fund Nationwide Variable Insurance Trust	—	$171.9K	0.05%	59,471 NS	FIGI
NVIT Small Cap Value Fund Nationwide Variable Insurance Trust	—	$158.5K	0.08%	54,831 NS	FIGI
VIP Disciplined Small Cap Portfolio Variable Insurance Products Fund II	—	$115.3K	0.02%	39,900 NS	FIGI
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX… VANGUARD INSTITUTIONAL INDEX FUNDS	—	$111.3K	0.00%	38,497 NS	FIGI
VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS	—	$110.1K	0.00%	38,094 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERMGNX
FIGI_COMPOSITEBBG000BM2SF8
FIGI_SHARE_CLASSBBG001S9C8R7
CIK0001125345
ISINUS5560991094
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.9
Model: deepseek
Rationale: MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based cancer therapies, fitting the biotechnology industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.